Welcome to our dedicated page for BAXTER INTERNATIONAL SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BAXTER INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BAXTER INTERNATIONAL's regulatory disclosures and financial reporting.
Baxter’s Q2-25 10-Q shows moderate top-line growth but margin pressure while the company reshapes its portfolio. Net sales from continuing operations rose 4% YoY to $2.81 bn (YTD +5% to $5.44 bn). Gross margin slipped 300 bp to 35.3% as cost of sales climbed, and hurricane-related costs added $17 m in the quarter. Operating income improved 7% YoY to $191 m, but YTD is down 15% to $249 m. Diluted EPS from continuing ops increased to $0.24 (vs. $0.19), bringing YTD EPS to $0.36. Total diluted EPS turned positive at $0.18 thanks to the absence of last year’s Kidney Care impairment.
Balance sheet strength improved markedly after the 1/31/25 divestiture of Kidney Care for ~$3.3 bn net cash. Assets fell to $21.0 bn while total liabilities dropped $5.0 bn to $13.8 bn. Short-term debt is nearly eliminated ($6 m vs. $2.13 bn) and long-term debt is down $0.9 bn to $9.49 bn following $3.5 bn repayments. Net cash at 6/30/25 stands at $1.69 bn. Baxter replaced its bridge loan with a $645 m term loan due 2027 and secured a new $2.2 bn multicurrency revolver (undrawn). Cash flow from operations was modest at $118 m YTD; financing outflows of $3.99 bn were covered by divestiture proceeds.
Key events: (1) Hurricane Helene charges total $115 m YTD. (2) Voluntary Class I recall of Novum IQ large-volume pump; distribution paused, reserve recorded (not material yet). (3) Quarterly dividend cut to $0.17 (-41% YoY).
Pzena Investment Management LLC filed Amendment No. 1 to its Schedule 13G on 15 July 2025, disclosing beneficial ownership of 39,708,226 shares of Baxter International Inc. (BAX) common stock, equal to 7.7 % of the outstanding class as of 30 June 2025.
The New York–based investment adviser reports sole voting power over 33,062,441 shares and sole dispositive power over the full 39.7 million shares; no shares are subject to shared voting/dispositive control. The filing states that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of Baxter.
This disclosure signals that a well-known value-oriented institutional investor maintains a sizable position above the 5 % threshold, information that may influence perceptions of Baxter’s shareholder base and potential governance dynamics. However, the filing contains no operational or financial performance data and does not indicate any activist intent.